Skip to main content
Erschienen in: Current Rheumatology Reports 4/2011

01.08.2011

Review of Clinical Registries of Psoriatic Arthritis: Lessons Learned? Value for the Future?

verfasst von: Dafna D. Gladman, Vinod Chandran

Erschienen in: Current Rheumatology Reports | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease associated with psoriasis, is a complex disease in terms of its clinical presentation, etiology, and pathogenesis. Musculoskeletal presentations include peripheral arthritis, spondylitis, enthesitis, and dactylitis. To learn about the course of and prognosis for such a complex disease, it is important to observe patients longitudinally so that all aspects of the disease are recognized. Several registries have been developed to evaluate the course of and prognosis for patients with PsA. Based on such registries, it has been shown that PsA is more severe than previously thought, and that progression of joint damage is related to joint inflammation. Such registries also have been used to determine genetic factors in PsA and to identify biomarkers for both susceptibility and expression of the disease. Drug registries also have been developed to document response to new therapies as well as the long-term adverse effects resulting from such therapies. It is hoped that an international effort currently on the way will further enhance the contribution of PsA patient registries to address the etiology, pathogenesis, and outcome of this complex disease.
Literatur
1.
Zurück zum Zitat Gladman DD, Ritchlin C, Helliwell PS. Psoriatic arthritis clinical registries and genomics. Ann Rheum Dis. 2005;64((Suppl II) ii):103–5. Gladman DD, Ritchlin C, Helliwell PS. Psoriatic arthritis clinical registries and genomics. Ann Rheum Dis. 2005;64((Suppl II) ii):103–5.
3.
Zurück zum Zitat Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32:181–201.PubMedCrossRef Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32:181–201.PubMedCrossRef
4.
Zurück zum Zitat Lambert JR, Wright V. Psoriatic spondylitis: a clinical and radiological description of the spine in psoriatic arthritis. Q J Med. 1977;46:411–25.PubMed Lambert JR, Wright V. Psoriatic spondylitis: a clinical and radiological description of the spine in psoriatic arthritis. Q J Med. 1977;46:411–25.PubMed
5.
Zurück zum Zitat • Gladman DD, Chandran V. Observational cohorts studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatol Online 2010;60:25–31. This paper describes the University of Toronto PsA program and the lessons learned from its registry. • Gladman DD, Chandran V. Observational cohorts studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatol Online 2010;60:25–31. This paper describes the University of Toronto PsA program and the lessons learned from its registry.
6.
Zurück zum Zitat • Nair RP, Duffin KC, Helms C, et al. The Collaborative Association Study of Psoriasis. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199–204. This study included patients from several psoriasis registries and identified several novel genes in the susceptibility to psoriasis and PsA. PubMedCrossRef • Nair RP, Duffin KC, Helms C, et al. The Collaborative Association Study of Psoriasis. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199–204. This study included patients from several psoriasis registries and identified several novel genes in the susceptibility to psoriasis and PsA. PubMedCrossRef
7.
Zurück zum Zitat Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33:834–9.PubMedCrossRef Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33:834–9.PubMedCrossRef
8.
Zurück zum Zitat Korendowych E, Dixey J, Cox B, et al. The Influence of the HLA-DRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis. J Rheumatol. 2003;30:96–101.PubMed Korendowych E, Dixey J, Cox B, et al. The Influence of the HLA-DRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis. J Rheumatol. 2003;30:96–101.PubMed
9.
Zurück zum Zitat McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778–83.CrossRef McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778–83.CrossRef
10.
Zurück zum Zitat Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis—a single-center study from the UK. J Rheumatol. 2010;37:2141214-4.CrossRef Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis—a single-center study from the UK. J Rheumatol. 2010;37:2141214-4.CrossRef
11.
Zurück zum Zitat Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis. Results from a single centre. I. Risk and causes of death. Arthritis Rheum. 1997;40:1868–72.PubMedCrossRef Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis. Results from a single centre. I. Risk and causes of death. Arthritis Rheum. 1997;40:1868–72.PubMedCrossRef
12.
Zurück zum Zitat Ali Y, Tom BDM, Schentag CT, et al. Improved survival in psoriatic arthritis (PsA) with calendar time. Arthritis Rheum. 2007;56:2708–14.PubMedCrossRef Ali Y, Tom BDM, Schentag CT, et al. Improved survival in psoriatic arthritis (PsA) with calendar time. Arthritis Rheum. 2007;56:2708–14.PubMedCrossRef
13.
Zurück zum Zitat Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol. 2000;27:1247–50.PubMed Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol. 2000;27:1247–50.PubMed
14.
Zurück zum Zitat Thumboo J, Uramoto K, Shbeeb MI, et al. Risk factors for the development of psoriatic arthritis: a population based nested case control study. J Rheumatol. 2002;29:757–62.PubMed Thumboo J, Uramoto K, Shbeeb MI, et al. Risk factors for the development of psoriatic arthritis: a population based nested case control study. J Rheumatol. 2002;29:757–62.PubMed
15.
Zurück zum Zitat Wilson FC, Icen M, Crowson CS, et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36:361–7.PubMedCrossRef Wilson FC, Icen M, Crowson CS, et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36:361–7.PubMedCrossRef
16.
Zurück zum Zitat Svensson B, Holmstrom G, Lindqvist U. Development and early experiences of a Swedish psoriatic arthritis register. Scand J Rheumatol. 2002;31:221–5.PubMedCrossRef Svensson B, Holmstrom G, Lindqvist U. Development and early experiences of a Swedish psoriatic arthritis register. Scand J Rheumatol. 2002;31:221–5.PubMedCrossRef
17.
Zurück zum Zitat • Lindqvist UR, Alenius GM, Husmark T, et al. The Swedish early psoriatic arthritis register—2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008;35:668–73. The Swedish early PsA registry includes patients with early PsA who are observed prospectively. PubMed • Lindqvist UR, Alenius GM, Husmark T, et al. The Swedish early psoriatic arthritis register—2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008;35:668–73. The Swedish early PsA registry includes patients with early PsA who are observed prospectively. PubMed
18.
Zurück zum Zitat Gladman DD, Ng Tung Hing E, Schentag CT, Cook R. Remission in psoriatic arthritis. J Rheumatol. 2001;28:1045–8.PubMed Gladman DD, Ng Tung Hing E, Schentag CT, Cook R. Remission in psoriatic arthritis. J Rheumatol. 2001;28:1045–8.PubMed
19.
Zurück zum Zitat Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460–8.CrossRef Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460–8.CrossRef
20.
Zurück zum Zitat • Reddy SM, Anandarajah AP, Fisher MC, et al. Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. J Rheumatol 2010;37:2566–72. This is a cross-sectional study from a US-based registry. It includes a large number of patients with RA and PsA observed over time. However, the information collected is limited. PubMedCrossRef • Reddy SM, Anandarajah AP, Fisher MC, et al. Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. J Rheumatol 2010;37:2566–72. This is a cross-sectional study from a US-based registry. It includes a large number of patients with RA and PsA observed over time. However, the information collected is limited. PubMedCrossRef
21.
Zurück zum Zitat Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis—clinical and laboratory analysis of 220 patients. Quart J Med. 1987;62:127–41.PubMed Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis—clinical and laboratory analysis of 220 patients. Quart J Med. 1987;62:127–41.PubMed
22.
Zurück zum Zitat Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809–12.PubMed Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809–12.PubMed
23.
Zurück zum Zitat Mader R, Gladman DD, Long J, Gough J, Farewell VT. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Investig Med. 1995;18:139–43. Mader R, Gladman DD, Long J, Gough J, Farewell VT. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Investig Med. 1995;18:139–43.
24.
Zurück zum Zitat Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J Rheumatol. 1995;22:241–5.PubMed Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J Rheumatol. 1995;22:241–5.PubMed
25.
Zurück zum Zitat Rahman P, Gladman DD, Zhou Y, Cook RJ. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol. 1998;25:1957–61.PubMed Rahman P, Gladman DD, Zhou Y, Cook RJ. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol. 1998;25:1957–61.PubMed
26.
Zurück zum Zitat Lee JCT, Gladman DD, Schentag CT, Cook RJ. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol. 2001;7:160–5.PubMedCrossRef Lee JCT, Gladman DD, Schentag CT, Cook RJ. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol. 2001;7:160–5.PubMedCrossRef
27.
Zurück zum Zitat Eder L, Chandran V, Shen H, et al. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology (Oxford). 2010;49:1361–6.CrossRef Eder L, Chandran V, Shen H, et al. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology (Oxford). 2010;49:1361–6.CrossRef
28.
Zurück zum Zitat • Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 2010;49:1367–73. This is the first study to systematically assess the response to intra-articular injections among patients with PsA. Almost half of the patients responded. The presence of damage was detrimental to response. Migration inhibitory factor polymorphisms did not predict response but were associated with recurrence. CrossRef • Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 2010;49:1367–73. This is the first study to systematically assess the response to intra-articular injections among patients with PsA. Almost half of the patients responded. The presence of damage was detrimental to response. Migration inhibitory factor polymorphisms did not predict response but were associated with recurrence. CrossRef
29.
Zurück zum Zitat • Eder L, Chandran V, Shen H, et al. The incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken) online 15/11/2010. This study demonstrated that the incidence of PsA among patients with psoriasis may be higher than what current figures indicate. This was a prospective cohort of patients with psoriasis observed according to the same standard protocol used in the PsA clinic. • Eder L, Chandran V, Shen H, et al. The incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken) online 15/11/2010. This study demonstrated that the incidence of PsA among patients with psoriasis may be higher than what current figures indicate. This was a prospective cohort of patients with psoriasis observed according to the same standard protocol used in the PsA clinic.
30.
Zurück zum Zitat Eder L, Loo T, Chandran V, et al. Environmental risk factors for psoriatic arthritis among patients with psoriasis: a case-control study. Arthritis Rheum. 2010;62 Suppl 10:S809. Eder L, Loo T, Chandran V, et al. Environmental risk factors for psoriatic arthritis among patients with psoriasis: a case-control study. Arthritis Rheum. 2010;62 Suppl 10:S809.
31.
Zurück zum Zitat Eder L, Chandran V, Pellett F, et al. The association of IL-13 polymorphism with psoriatic arthritis among psoriasis patients. Arthritis Rheum. 2010;62 Suppl 10:S830. Eder L, Chandran V, Pellett F, et al. The association of IL-13 polymorphism with psoriatic arthritis among psoriasis patients. Arthritis Rheum. 2010;62 Suppl 10:S830.
32.
Zurück zum Zitat Eder L, Pellett F, Chandran V, et al. HLA-Cw*06 allele increases the duration of time between the onset of psoriasis and psoriatic arthritis. Arthritis Rheum. 2010;62 Suppl 10:S220. Eder L, Pellett F, Chandran V, et al. HLA-Cw*06 allele increases the duration of time between the onset of psoriasis and psoriatic arthritis. Arthritis Rheum. 2010;62 Suppl 10:S220.
33.
Zurück zum Zitat • Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the Danish nationwide DANBIO registry. Arthritis Rheum online 27/10/2010. PMID: 20981816. The use of biologics registries to determine drug survival and toxicity was demonstrated by this study from the Danish registry. • Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the Danish nationwide DANBIO registry. Arthritis Rheum online 27/10/2010. PMID: 20981816. The use of biologics registries to determine drug survival and toxicity was demonstrated by this study from the Danish registry.
34.
Zurück zum Zitat Carmona L, Descalzo MA, Ruiz-Montesinos D, et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology. 2011;50:85–92.PubMedCrossRef Carmona L, Descalzo MA, Ruiz-Montesinos D, et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology. 2011;50:85–92.PubMedCrossRef
35.
Zurück zum Zitat Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:R52.PubMedCrossRef Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:R52.PubMedCrossRef
36.
Zurück zum Zitat Simard JF, Arkema EV, Sundstrom A, et al. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford). 2011;50:204–13.CrossRef Simard JF, Arkema EV, Sundstrom A, et al. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford). 2011;50:204–13.CrossRef
37.
Zurück zum Zitat Aletaha D. Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data. Arthritis Res Ther. 2009;11:112.PubMedCrossRef Aletaha D. Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data. Arthritis Res Ther. 2009;11:112.PubMedCrossRef
38.
Zurück zum Zitat Brockbank J, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis (PsA): a marker for disease severity? Ann Rheum Dis. 2005;62:188–90.CrossRef Brockbank J, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis (PsA): a marker for disease severity? Ann Rheum Dis. 2005;62:188–90.CrossRef
39.
Zurück zum Zitat Queiro R, Torre JC, Belzunegui J, et al. Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum. 2002;31:264–70.PubMedCrossRef Queiro R, Torre JC, Belzunegui J, et al. Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum. 2002;31:264–70.PubMedCrossRef
40.
Zurück zum Zitat Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis. Results from a single centre. Ann Rheum Dis. 2007;66:370–6.PubMedCrossRef Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis. Results from a single centre. Ann Rheum Dis. 2007;66:370–6.PubMedCrossRef
41.
Zurück zum Zitat Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis (PsA). Ann Rheum Dis. 2009;68:1131–5.PubMedCrossRef Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis (PsA). Ann Rheum Dis. 2009;68:1131–5.PubMedCrossRef
42.
Zurück zum Zitat Rohekar S, Tom BD, Hassa A, et al. Malignancy in psoriatic arthritis. Arthritis Rheum. 2008;58:82–7.PubMedCrossRef Rohekar S, Tom BD, Hassa A, et al. Malignancy in psoriatic arthritis. Arthritis Rheum. 2008;58:82–7.PubMedCrossRef
43.
Zurück zum Zitat • Chandran V, Cook RJ, Edwin J, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010;49:1399–1405. The study demonstrated that there are biomarkers for susceptibility to psoriatic disease, some of which actually distinguish between patients with psoriasis alone and those with PsA. CrossRef • Chandran V, Cook RJ, Edwin J, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010;49:1399–1405. The study demonstrated that there are biomarkers for susceptibility to psoriatic disease, some of which actually distinguish between patients with psoriasis alone and those with PsA. CrossRef
44.
Zurück zum Zitat Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111:821–31.PubMed Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111:821–31.PubMed
45.
Zurück zum Zitat Chiu YG, Shanmugarajah S, Oanpento B, et al. DC-STAMP (dendritic cell specific transmembrane protein), a potential biomarker to predict the risk of psoriasis patients in developing psoriatic arthritis. Arthritis Rheum. 2101;62 Suppl 10:S217. Chiu YG, Shanmugarajah S, Oanpento B, et al. DC-STAMP (dendritic cell specific transmembrane protein), a potential biomarker to predict the risk of psoriasis patients in developing psoriatic arthritis. Arthritis Rheum. 2101;62 Suppl 10:S217.
46.
Zurück zum Zitat Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34:J314.PubMedCrossRef Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34:J314.PubMedCrossRef
47.
Zurück zum Zitat Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study reveals association of psoriasis with TRAF3IP2. Nat Genet. 2010;42:991–5.PubMedCrossRef Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study reveals association of psoriasis with TRAF3IP2. Nat Genet. 2010;42:991–5.PubMedCrossRef
48.
Zurück zum Zitat • Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010;42:1000–4. There are now two large genome-wide association studies that identified patients with PsA. A meta-analysis of those studies identified three new psoriasis and PsA susceptibility loci. PubMedCrossRef • Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010;42:1000–4. There are now two large genome-wide association studies that identified patients with PsA. A meta-analysis of those studies identified three new psoriasis and PsA susceptibility loci. PubMedCrossRef
49.
50.
Zurück zum Zitat Toloza SMA, Valle-Oñate R, Espinoza LR. Psoriatic arthritis in South and Central America. Curr Rheum Rep 2011 (in press) Toloza SMA, Valle-Oñate R, Espinoza LR. Psoriatic arthritis in South and Central America. Curr Rheum Rep 2011 (in press)
Metadaten
Titel
Review of Clinical Registries of Psoriatic Arthritis: Lessons Learned? Value for the Future?
verfasst von
Dafna D. Gladman
Vinod Chandran
Publikationsdatum
01.08.2011
Verlag
Current Science Inc.
Erschienen in
Current Rheumatology Reports / Ausgabe 4/2011
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-011-0182-x

Weitere Artikel der Ausgabe 4/2011

Current Rheumatology Reports 4/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.